Jun 12, 2020
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
Jun 06, 2020
AbbVie Presents Data Showing RINVOQ(TM) (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
Jun 04, 2020
New Long-term Data from RINVOQ(TM) (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
Jun 03, 2020
EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
Jun 01, 2020
Despite Increased Competition from the Recent Launch of Janssen's Stelara, Takeda's Entyvio Continues to Shine as a Leading Ulcerative Colitis Treatment
Jun 01, 2020
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ(TM) (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
May 27, 2020
AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
May 08, 2020
AbbVie Completes Transformative Acquisition of Allergan
May 05, 2020
AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan
Apr 10, 2020
Visiongain Report Provides Critical Market-led Data on the $6.6bn Biosimilar Monoclonal Antibodies Market
Apr 01, 2020
Global Biosimilars Market (2020 to 2025) - New Indications and the Patent Expiry of Biologic Products Present Lucrative Opportunities
Mar 31, 2020
Fosun Pharma Announces 2019 Annual Results
Mar 23, 2020
Global Hidradenitis Suppurativa (HS) Industry Assessment, 2020 Featuring InflaRx, Novartis Pharma, Incyte Corp, UCB Biopharma, and Janssen Pharma
Feb 05, 2020
RINVOQ(TM) (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
Jan 27, 2020
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
Jan 14, 2020
New Head-to-Head Phase 3 Data Show SKYRIZI(TM) (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
Dec 23, 2019
Global Therapeutic Proteins Market Report 2020: Market was Valued at $93.14 Billion in 2018 and is Expected to Grow to $172.87 Billion through 2022 - ResearchAndMarkets.com
Dec 18, 2019
AbbVie Receives European Commission Approval of RINVOQ(TM) (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Dec 17, 2019
The Biosimilars Market in the US: 2019 Payer Insights Report Featuring 47 Insights Supported by 199 Directly Quoted Comments from Industry Experts
Dec 16, 2019
Dermatology Drugs Market by Treatment, by Drug, by Therapy Area, by Prescription Mode, by Distribution Channel, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023